Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 8/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069616 | 0.88 | PTGS2 (0.55) | PTGER1PTGS2PTGS1 | |
| SCHEMBL6660825 | 0.81 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL6658818 | 0.79 | PTGS2 (0.43) | PTGS2PTGS1NR1H2NR1H3 | |
| SCHEMBL6658777 | 0.79 | PTGS2 (0.47) | PTGS2PTGS1NR1H2NR1H3 | |
| SCHEMBL6663452 | 0.79 | PTGS2 (0.50) | PTGS2PTGS1NR1H2NR1H3 | |
| SCHEMBL6069633 | 0.78 | PTGS2 (0.51) | PTGS2PTGS1CYP2C9NR1H2NR1H3 | |
| SCHEMBL6659133 | 0.78 | PTGS2 (0.58) | PTGS2PTGS1NR1H2NR1H3 | |
| SCHEMBL6069927 | 0.75 | PTGS2 (0.49) | PTGS2PTGS1NR1H2NR1H3 | |
| SCHEMBL6069536 | 0.75 | EPHB4 (0.54) | PTGS2PTGS1 | |
| SCHEMBL6069781 | 0.75 | PTGS2 (0.49) | PTGS2PTGS1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060715-B2 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-06-13 | — | — | US | disclosed |
| US-20050009875-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK CANADA INC. (CA) | 2005-01-13 | — | — | US | disclosed |
| US-6812346-B2 | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS; ANALGESICS | MERCK FROSST CANADA AND CO. (CA) | 2004-11-02 | — | — | US | disclosed |
| EP-1024696-A4 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040029921-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. | 2004-02-12 | — | — | US | disclosed |
| EP-0912518-B1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-09-10 | — | — | EP | disclosed |
| US-6596736-B2 | Well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non- toxic therapeutically effective amount of a compound of Formula I. pain, dysmenorrhea, myositis, | MERCK & CO., INC. | 2003-07-22 | — | — | US | disclosed |
| US-20030065011-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. | 2003-04-03 | — | — | US | disclosed |
| US-6245797-B1 | ADMINISTERING MIXTURE OF ENZYME INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | disclosed |
| EP-1024696-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | Merck & Co., Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| US-6071936-A | ANTIINFLAMMATORY AGENTS ANTIPYRETICS, ANALGESICS, ANTICARCINOGENIC AGENTS, SIDE EFFECT REDUCTION | MERCK FROSST CANADA & CO. (CA) | 2000-06-06 | — | — | US | disclosed |
| US-6001843-A | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK & CO., INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0912518-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-05-06 | — | — | EP | disclosed |
| WO-1999020110-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| US-5861419-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; ETORICOXIB PATENT | MERCK FROSST CANAD, INC. (CA) | 1999-01-19 | — | — | US | disclosed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009875-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGER1 7/4885TBXA2R 27/4885IKBKB 276/4885 |
| US-20030065011-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGER1 5/4885TBXA2R 29/4885IKBKB 329/4885 |
| US-20040029921-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGER1 5/4885TBXA2R 29/4885IKBKB 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.